Finebiotics Pharma Limited
Finebiotics Pharma Limited is a Public Non-govt company company incorporated in 2004 and based in Gujarat, India. Finebiotics Pharma Limited operates in Chemical substances used in the manufacture of anti-biotic, manufacturing (NIC 24231) with authorized capital of ₹11.50 Cr and paid-up capital of ₹11.50 Cr. For 2023-24, the company reported revenue of ₹33.42 Cr and a net loss of ₹24.58 L. The board has 1 active director. RegisterKaro's provisional Compliance Health Score for the company is 67/100 (grade C), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
FINEBIOTICS PHARMA LIMITED is the legal entity of Fine Biotics.
Quick facts
Directors
1 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | +13d | filed |
| MGT-7 | FY2024-25 | 26 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 21 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | +7d | filed |
| MGT-7 | FY2022-23 | 20 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Finebiotics Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 458068376 | Kotak Mahindra Bank Ltd(Bank) | ₹12.64 Cr | 19 Sep 2020 | Open |
| 401556533 | Axis Bank Ltd(Bank) | ₹7.33 Cr | 12 Mar 2020 | Satisfied |
| 326321707 | Axis Bank Ltd(Bank) | ₹4.40 Cr | 04 Jul 2021 | Satisfied |
| 502034195 | HDFC Bank Ltd(Bank) | ₹2.62 Cr | 27 Jan 2022 | Satisfied |
| 236865030 | ICICI Bank Ltd(Bank) | ₹24.03 Cr | 27 Jan 2023 | Open |
Charge IDs, lenders & amounts for Finebiotics Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2022-23 | — | ||||
| 2019-20 | — | ||||
| 2017-18 | — | ||||
| 2014-15 | — |
Detailed Financials
4 FYs| Line item | 2023-24 | 2022-23 | 2019-20 | 2017-18 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | +12.0% | +81.0% | — | |
| Profit after Tax2023-24 | — | — | — | |
| Net Worth2023-24 | -10.0% | -1.0% | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2014-15 | -28.97% | — | -17.05% | -8.69% | — | |||
| 2017-18 | +0.63% | +334.05% | +1.38% | +0.77% | — | |||
| 2019-20 | +0.66% | +57.58% | +2.18% | +1.00% | — | |||
| 2022-23 | -6.49% | +10.01% | -29.28% | -11.66% | — | |||
| 2023-24 | -0.74% | +25.47% | -4.34% | -1.80% | — |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 3 | 81,28,442 | 71.09% |
| Institutional Investors | 2 | 14,41,219 | 12.60% |
| Public & Others | 23 | 18,64,290 | 16.30% |
Promoter, institutional & public holding for Finebiotics Pharma Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
19 peersTop 10 in Chemical substances used in the manufacture of anti-biotic, manufacturing
by healthView all ›Events & timeline
2External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.